MX343193B - Administracion segura de desmopresina. - Google Patents

Administracion segura de desmopresina.

Info

Publication number
MX343193B
MX343193B MX2012000066A MX2012000066A MX343193B MX 343193 B MX343193 B MX 343193B MX 2012000066 A MX2012000066 A MX 2012000066A MX 2012000066 A MX2012000066 A MX 2012000066A MX 343193 B MX343193 B MX 343193B
Authority
MX
Mexico
Prior art keywords
safe
desmopressin
dispensers
desmopressin administration
nocturia
Prior art date
Application number
MX2012000066A
Other languages
English (en)
Other versions
MX2012000066A (es
Inventor
Seymour Fein
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43356719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX343193(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2012000066A publication Critical patent/MX2012000066A/es
Publication of MX343193B publication Critical patent/MX343193B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/008—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised by squeezing, e.g. using a flexible bottle or a bulb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Mechanical Engineering (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un dispositivo de rocío intranasal, caracterizado porque comprende un depósito que tiene dispuesto en el mismo una composición que comprende desmopresina, una salida en comunicación con el depósito y que tiene una boquilla que desde ahí una dosis de desmopresina en la forma de un penacho se expulsa durante un intervalo de tiempo, el penacho comprende un volumen de gotitas que se mueven en conjunto que definen un volumen cónico que tiene un eje central y un vértice en la boquilla del dispositivo de rocío, en donde la densidad de las gotitas (número de gotitas por volumen unitario) dentro del volumen cónico se incrementa en una dirección normal al eje, las gotitas en conjunto comprenden entre aproximadamente 0.05 µg y 5.0 µg de desmoprisina, el penacho sirve para incrementar el contacto de las gotitas con las superficies de la mucosa luminal intranasal, en donde dichas gotitas comprende adicionalmente : (a) una emulsión de aceite en agua; y (b) un mejorador de permeación.
MX2012000066A 2009-06-18 2010-06-15 Administracion segura de desmopresina. MX343193B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26895409P 2009-06-18 2009-06-18
PCT/US2010/038663 WO2010147981A1 (en) 2009-06-18 2010-06-15 Safe desmopressin administration

Publications (2)

Publication Number Publication Date
MX2012000066A MX2012000066A (es) 2012-02-29
MX343193B true MX343193B (es) 2016-10-26

Family

ID=43356719

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000066A MX343193B (es) 2009-06-18 2010-06-15 Administracion segura de desmopresina.

Country Status (15)

Country Link
US (3) US9539302B2 (es)
EP (4) EP2442821B1 (es)
JP (3) JP6073678B2 (es)
KR (2) KR101792696B1 (es)
CN (2) CN102647993A (es)
AU (2) AU2010260211B2 (es)
BR (1) BRPI1015046A2 (es)
CA (1) CA2765221C (es)
DK (4) DK3278809T3 (es)
ES (3) ES2773694T3 (es)
MX (1) MX343193B (es)
PL (4) PL2442821T3 (es)
PT (3) PT2442821T (es)
RU (2) RU2015144851A (es)
WO (1) WO2010147981A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
RU2472539C2 (ru) 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CA2747998C (en) 2008-12-22 2016-05-31 Allergan, Inc. Safe desmopressin administration
KR101792696B1 (ko) 2009-06-18 2017-11-02 알레간 인코포레이티드 안전한 데스모프레신 투여
JP2014518270A (ja) * 2011-06-27 2014-07-28 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム トロイダル医薬製剤
WO2014055801A1 (en) * 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
ES2744542T3 (es) * 2013-03-15 2020-02-25 Robert I Henkin Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos
DK3024474T3 (da) 2013-07-23 2022-03-28 Serenity Pharmaceuticals Llc Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist
WO2015013453A1 (en) 2013-07-23 2015-01-29 Allergan, Inc. Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
KR20170097045A (ko) 2014-11-20 2017-08-25 알레간 인코포레이티드 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물
WO2017023162A1 (en) * 2015-08-04 2017-02-09 Inqpharm Group Sdn Bhd A nasal composition
MX2021007213A (es) * 2018-12-19 2021-09-23 Grace therapeutics Inc Composicion terapeutica de lidocaina intranasal.
USD959279S1 (en) 2020-04-07 2022-08-02 VB Brands LLC Spray bottle
US11272834B2 (en) * 2020-04-13 2022-03-15 AIMIC Corp. Imaging system and method for quality and dosage control of anesthetics applied by a spray nozzle

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS171787B1 (es) 1973-11-09 1976-11-29
US4148787A (en) 1976-05-24 1979-04-10 Ferring Ab Antidiuretically effective polypeptide and a process for preparing the same
US4285858A (en) 1979-10-30 1981-08-25 Mt. Sinai School Of Medicine Of The City University Of N.Y. Vasopressin analogs
US4263283A (en) 1980-05-16 1981-04-21 Ferring Pharmaceuticals, Inc. Method for prophylaxis and/or treatment of sickle cell disease
CA1208558A (en) 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4771769A (en) 1982-12-20 1988-09-20 Schering Corporation Hand held metered spray dispenser
US4548922A (en) 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
SE8306367L (sv) 1983-11-18 1985-05-19 Ferring Ab Antidiuretiskt verkande farmaceutiskt preparat
US4863737A (en) 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
DE3690626C2 (de) 1985-12-04 1997-05-15 Dean Hsieh Arzneimittel, enthaltend neben einer wirksamen Arzneistoffmenge ein Lacton oder cyclisches Keton
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4878892A (en) 1987-02-10 1989-11-07 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
US5112804A (en) 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US4944429A (en) 1987-08-28 1990-07-31 Schering Corporation Manually-operable spray dispenser with locking mechanism
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5154122A (en) 1989-10-20 1992-10-13 Sol Goldschmidt Shipping device for suspended piece goods
JP2951681B2 (ja) 1990-02-23 1999-09-20 株式会社資生堂 経粘膜投与用薬剤組成物
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
CN1060980A (zh) 1990-10-26 1992-05-13 蔡东林 多用电控自控微型喷雾器
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
TW279133B (es) 1990-12-13 1996-06-21 Elan Med Tech
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US5298256A (en) 1992-04-28 1994-03-29 Corint, Ltd. Desmopressin buccal patch composition
IT1255895B (it) 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
CA2090738C (en) 1993-02-24 1996-05-21 Hema-Quebec Use of paf
SE9300937L (sv) 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
US5500413A (en) 1993-06-29 1996-03-19 Ferring Ab Process for manufacture of 1-deamino-8-D-arginine vasopressin
WO1995001368A1 (en) 1993-06-29 1995-01-12 Ferring B.V. Improved synthesis of cyclic peptides
HU221617B1 (hu) * 1993-06-29 2002-12-28 Ferring B.V. Vizes készítmény dezmopresszin nazális adagolására
US5985835A (en) 1993-12-23 1999-11-16 Ferring B.V. Desmopressin for nocturia, incontinence and enuresis
US5482931A (en) 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5388766A (en) * 1993-09-22 1995-02-14 The Procter & Gamble Company High pressure atomization systems for high viscosity products
US5358551A (en) 1993-11-16 1994-10-25 Ccpi, Inc. Turbulence inhibiting tundish and impact pad and method of using
CA2176927C (en) 1993-11-17 2010-03-23 Seang H. Yiv Transparent liquid for encapsulated drug delivery
WO1995018602A1 (en) 1994-01-11 1995-07-13 Alkermes Controlled Therapeutics, Inc. ORAL DOSAGE FORM OF DESMOPRESSIN (dDAVP)
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
US5613770A (en) 1994-05-16 1997-03-25 Lite Corporation Apparatus for securing component panels in a lighting fixture
JP3246233B2 (ja) 1994-11-09 2002-01-15 三菱マテリアル株式会社 多孔質セラミック焼結体製造用混合原料
EP0840630B1 (en) 1995-06-07 2009-05-06 O'NEIL, Christine Patient controlled drug delivery device
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
DE19610457A1 (de) 1996-03-16 1997-09-18 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
DE19623030A1 (de) 1996-06-08 1997-12-11 Pfeiffer Erich Gmbh & Co Kg Austrag-Einheit für Medien
US5763398A (en) 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
DE19627228A1 (de) 1996-07-05 1998-01-08 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
GB9614235D0 (en) 1996-07-06 1996-09-04 Danbiosyst Uk Composition for enhanced uptake of polar drugs from mucosal surfaces
WO1998009645A1 (fr) 1996-09-04 1998-03-12 Dott Research Laboratory Compositions medicamenteuses contenant des peptides, destinees a l'administration orale
DE19642976A1 (de) 1996-10-18 1998-04-23 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
HU224587B1 (hu) 1997-09-12 2005-11-28 Telefonaktiebolaget Lm Ericsson (Publ). Eljárás és berendezés mobiltelefonhoz
AU9496798A (en) 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
RS49890B (sr) 1998-07-08 2008-08-07 Kirin-Amgen Inc., Preparat u formi praška koji sadrži medicinsko sredstvo velike molekulske težine za primenu preko sluzokože
US6355270B1 (en) 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
EP1071517B1 (de) 1999-02-14 2008-04-02 Ing. Erich Pfeiffer GmbH Spender für fliessfähige medien
AR014640A1 (es) 1999-02-23 2001-03-28 Univ Nac Quilmes UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
PT1183060E (pt) * 1999-05-20 2006-06-30 Kos Life Sciences Inc Sistema de atomizacao de baixa forca de nebulizacao e baixa retencao
DE19938798A1 (de) 1999-08-16 2001-03-01 Pfeiffer Erich Gmbh & Co Kg Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte
DE19940236A1 (de) 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
DE19942792A1 (de) 1999-09-08 2001-03-15 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
AU3221401A (en) 1999-11-30 2001-06-12 Rajesh Jain Fast dissolving composition with prolonged sweet taste
CN1479609A (zh) 2000-08-11 2004-03-03 现代药品工业株式会社 肽的经口递送
GB0028575D0 (en) 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
DE10110742A1 (de) 2001-02-28 2002-09-05 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
CN1283365C (zh) 2001-09-21 2006-11-08 艾里希普费弗工程师有限公司 具有一个介质容器和用于该容器的泵机构的配量装置
WO2003026804A1 (de) 2001-09-21 2003-04-03 Ing. Erich Pfeiffer Gmbh Dosiervorrichtung mit einem medienspeicher sowie einer pumpvorrichtung
CA2460651C (en) 2001-09-21 2011-06-07 Ing. Erich Pfeiffer Gmbh Dosing device with a pumping device
US20050025824A1 (en) 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
EP1458353A1 (en) 2001-12-19 2004-09-22 ALZA Corporation Formulation dosage form for the controlled delivery of ther apeutic agents
JP5462429B2 (ja) 2002-01-16 2014-04-02 アステラス製薬株式会社 経口吸収改善用医薬組成物
WO2003094886A2 (en) 2002-05-07 2003-11-20 Ferring Bv Desmopressin in an orodispersible dosage form
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
ITMI20021684A1 (it) 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
CN1233952C (zh) 2003-09-04 2005-12-28 上海交通大学 调节入口烟气流量分配的辐射屏式过热器
EP2322195A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
ATE474591T1 (de) 2003-12-08 2010-08-15 Cpex Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung
EP1729724A4 (en) 2003-12-31 2008-07-23 Cydex Inc INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
DE102004044344A1 (de) 2004-09-09 2006-03-30 Ing. Erich Pfeiffer Gmbh Dosiervorrichtung
DE102004050679A1 (de) 2004-10-13 2006-04-20 Ing. Erich Pfeiffer Gmbh Dosiervorrichtung
DE102004050977A1 (de) 2004-10-14 2006-04-20 Ing. Erich Pfeiffer Gmbh Dosiervorrichtung für wenigstens ein Medium
EP1891790A1 (fr) 2005-06-17 2008-02-27 France Télécom Procede de gestion de l'execution par un serveur d'une application offrant au moins un service multimedia interactif a au moins un terminal, produit programme d'ordinateur et serveur correspondants
WO2007022345A2 (en) 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
CN1785448A (zh) 2005-11-11 2006-06-14 广东工业大学 医用防染式药雾吸入喷嘴
DE102006008874B4 (de) 2006-02-21 2012-06-21 Ing. Erich Pfeiffer Gmbh Dosiervorrichtung mit einer manuell betätigbaren Pumpeinrichtung
CA2654207A1 (en) 2006-06-08 2007-12-21 Cpex Pharmaceuticals, Inc. Insulin composition
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
CN106038481A (zh) * 2007-06-28 2016-10-26 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
RU2472539C2 (ru) 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
US20100160214A1 (en) 2008-12-22 2010-06-24 Serenity Pharmaceuticals Corporation Desmopressin composition
CA2747998C (en) * 2008-12-22 2016-05-31 Allergan, Inc. Safe desmopressin administration
KR101792696B1 (ko) 2009-06-18 2017-11-02 알레간 인코포레이티드 안전한 데스모프레신 투여
TWI598335B (zh) 2012-10-25 2017-09-11 Ｗ Ｒ 康格雷氏公司 用於製造吡啶及其烷基衍生物之改良方法、觸媒
DK3024474T3 (da) * 2013-07-23 2022-03-28 Serenity Pharmaceuticals Llc Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist

Also Published As

Publication number Publication date
JP2016014059A (ja) 2016-01-28
PL3679941T3 (pl) 2023-04-17
CN102647993A (zh) 2012-08-22
MX2012000066A (es) 2012-02-29
WO2010147981A1 (en) 2010-12-23
EP3679941A1 (en) 2020-07-15
KR101792696B1 (ko) 2017-11-02
US11419914B2 (en) 2022-08-23
DK2442821T3 (en) 2017-10-02
EP2442821A4 (en) 2013-07-31
AU2010260211A1 (en) 2012-01-12
PT2442821T (pt) 2017-09-29
US9539302B2 (en) 2017-01-10
EP3679941B1 (en) 2022-08-10
DK4104848T3 (da) 2024-01-02
PT3679941T (pt) 2022-11-10
AU2016204306B2 (en) 2018-03-29
US20180369320A1 (en) 2018-12-27
CA2765221A1 (en) 2010-12-23
AU2010260211B2 (en) 2016-04-21
EP3278809A1 (en) 2018-02-07
PL2442821T3 (pl) 2018-04-30
ES2773694T3 (es) 2020-07-14
RU2012101619A (ru) 2013-07-27
US20120149643A1 (en) 2012-06-14
ES2638815T3 (es) 2017-10-24
RU2569756C2 (ru) 2015-11-27
JP2017160263A (ja) 2017-09-14
US20230218709A1 (en) 2023-07-13
PL4104848T3 (pl) 2024-03-25
DK3278809T3 (da) 2020-02-24
DK3679941T3 (da) 2022-11-14
BRPI1015046A2 (pt) 2016-04-12
PL3278809T3 (pl) 2020-06-15
EP2442821A1 (en) 2012-04-25
JP2012530708A (ja) 2012-12-06
CA2765221C (en) 2017-10-03
JP6073678B2 (ja) 2017-02-01
KR20120046176A (ko) 2012-05-09
EP3278809B1 (en) 2019-11-20
ES2929471T3 (es) 2022-11-29
KR20170123713A (ko) 2017-11-08
AU2016204306A1 (en) 2016-07-14
EP2442821B1 (en) 2017-06-14
JP6166320B2 (ja) 2017-07-19
CN108295241A (zh) 2018-07-20
EP4104848A1 (en) 2022-12-21
PT4104848T (pt) 2024-01-04
KR102059255B1 (ko) 2019-12-24
RU2015144851A (ru) 2019-01-10
JP6501826B2 (ja) 2019-04-17
EP4104848B1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
MX2012000066A (es) Administracion segura de desmopresina.
NZ593613A (en) Intranasal desmopressin administration
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
EP3195868A3 (en) Therapeutic use of a tlr agonist and combination therapy
SG10201700310PA (en) Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease
NZ701038A (en) Treating acute decompensated heart failure with relaxin
MX2011009757A (es) Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico.
NZ612455A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
PH12018500023A1 (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
WO2011020064A3 (en) Low-profile intraluminal light delivery system and methods of using the same
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
NZ598600A (en) Therapeutic agent for rhinitis
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
WO2010107251A2 (ko) 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물
GEP20146067B (en) Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases
CN102380167B (zh) 口腔溃疡护理治疗仪
CN103751732A (zh) 一种治疗咳嗽的处方
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
WO2011061554A3 (en) Pharmaceutical composition for the treatment of bladder disorders
UA96065C2 (ru) Способ прогнозирования эффективности терапии глюкокортикоидами и цитостатиками у больных детей с гломерулонефритом с нефротическим синдромом
Yan et al. Treatment report: Combination use of praziquantel and albendazole in an Echinococcosis patient with multi-infected organs

Legal Events

Date Code Title Description
FG Grant or registration